Hangzhou Bio-Sincerity Pharma-Tech (SHE:301096) received clinical trial approval from China's National Medical Products Administration for its self-developed BIOS0635-048 tablets, according to a Monday after-hours filing with the Shenzhen bourse.
The drug targets advanced solid tumors, inhibiting endocrine receptors, and can regulate the cyell cycle.
Cauldron Energy (ASX:CXU) said Southern Geoscience has provided a further installment of processed passive seismic interpretations for its Yanrey Uranium Project in Western Australia, covering the Manyingee Southeast, Manyingee West, Ashburton East and Cosgrove locations, according to a Monday Australian bourse filing.The company said the most significant finding from the third installment is the delineation of a separate, previously undiscovered and untested arm of the Manyingee South palaeochannel, with passive seismic continuing to prove a cost-effective method for identifying the margins of palaeochannels and increasing drilling effectiveness.The company's shares fell almost 7% in recent Monday trade.
Infoline Tec Group (KLSE:INFOTEC) is seeking shareholders' approval for its wholly-owned subsidiary, Infoline IT Solutions, to acquire two adjoining intermediate units from Huayi (SEA) and Orionis Technology, respectively, for a total of 18.6 Malaysian ringgit, according to a Monday filing to Bursa Malaysia.The investor approval will be sought at the upcoming extraordinary general meeting on Aug. 28.The company's shares were down nearly 6% in recent trade.The acquired units will be used to set up the company's new head office. Both acquisitions will be done on a 99-year lease up to Oct. 18, 2106.Infoline's board is also seeking shareholders' nod for a proposed employees' share option scheme (ESOS) covering up to 10% of issued share capital for eligible directors and employees. The scheme will be valid for five years with an option for a further five-year extension.
Hanwha Aerospace (KRX:012450) secured a framework contract with an unnamed entity to supply aerospace products, exceeding 2.5% of its most recent annual sales, according to a Monday filing with the Korea Exchange.The company said that the contract is subject to disclosure requirements, and the details of the agreement are withheld due to business confidentiality.